Insmed Q1 revenue jumps 230%, net loss narrows

Insmed

07/05/2026 12:15

Overview

U.S. biopharma firm's Q1 revenue rose 230% yr/yr, driven by BRINSUPRI launch and ARIKAYCE growth

Company posted net loss of $163.6 mln, narrower than prior year

Insmed reiterated 2026 revenue guidance for BRINSUPRI and ARIKAYCE

Outlook

Company reiterates 2026 BRINSUPRI revenue guidance of at least $1 bln

Company maintains 2026 ARIKAYCE revenue guidance of $450 mln to $470 mln

Insmed expects to submit a supplemental new drug application for ARIKAYCE in H2 2026

Result Drivers

BRINSUPRI LAUNCH - Strong U.S. launch of BRINSUPRI drove 44% sequential revenue growth for the product and was the primary driver of total company revenue growth

ARIKAYCE INTERNATIONAL GROWTH - ARIKAYCE revenue rose 6% yr/yr, with growth driven by international markets

LOWER MANUFACTURING COSTS - Cost of product revenues as a percentage of revenues decreased due to BRINSUPRI's lower manufacturing costs

Company press release: ID:nPn688mb9a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.76
Q1 Net Income
-$163.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Insmed Inc is $212.00, about 54.6% above its May 6 closing price of $137.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)